| Literature DB >> 33110922 |
Ioana Damian1,2, Simona Delia Nicoara1,3.
Abstract
BACKGROUND: Numerous studies confirmed the main role of the inner blood-retinal barrier in the development of Diabetic Macular Oedema (DMO). Lately, the focus of research shifted towards the external retinal barrier with potential involvement in the pathogenesis of DMO.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33110922 PMCID: PMC7578732 DOI: 10.1155/2020/8880586
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Figure 1Flow diagram illustrating the study selection process. AMD: age-related macular degeneration; anti-VEGF: anti-vascular endothelial growth factor; PPV: pars plana vitrectomy; ERM: epiretinal membrane, Q: OCT segmentation quality; NPDR-DMO: nonproliferative diabetic retinopathy-diabetic macular oedema; PDR-DMO: proliferative diabetic retinopathy-diabetic macular oedema.
Figure 2Retinal layer segmentation.
Baseline characteristics of the patients included in the study.
| Control ( | NPDR-DMO ( | PDR-DMO ( |
| |
|---|---|---|---|---|
| Age, years | 53.3 ± 14.19 | 61 ± 8.57 | 57.8 ± 9.56 | 0.151 |
| Gender (F/M) | 20 (55.6%)/16 (44.4%) | 9 (50%)/9 (50%) | 13 (68.4%)/6 (31.6%) | 0.497 |
| BCVA, letters | 83.75 ± 2.50 | 55.52 ± 24.46 | 45.94 ± 27.57 | <0.00001 |
∗The results are expressed as mean ± SD or frequency with percentages in parentheses. N: number; F: female; M: male; BCVA: best-corrected visual acuity; NPDR-DMO: nonproliferative diabetic retinopathy-diabetic macular oedema; PDR-DMO: proliferative diabetic retinopathy-diabetic macular oedema.
RPE thickness and volume in each ETDRS macular map quadrant.
| RPE | Control | NPDR-DMO | PDR-DMO | Kruskal-Wallis |
|---|---|---|---|---|
| Central subfield ( | 16.2 ± 1.7 | 18.6 ± 6.9 | 15.8 ± 2.8 |
|
| Central minimum ( | 12.4 ± 1.3 | 8.3 ± 4.3 | 8.2 ± 2.8 |
|
| Central maximum ( | 21.4 ± 2.6 | 41.1 ± 27.3 | 32.8 ± 11.6 |
|
| Central volume (mm3) | 0.0106 ± 0.0023 | 0.0117 ± 0.0038 | 0.0111 ± 0.0031 | 0.972 |
| Temporal inner quadrant ( | 14.3 ± 1.3 | 14.5 ± 1.7 | 14 ± 2.58 | 0.173 |
| Temporal inner volume (mm3) | 0.0218 ± 0.0038 | 0.0217 ± 0.0038 | 0.0216 ± 0.0050 | 0.993 |
| Nasal inner quadrant ( | 15.3 ± 1.6 | 15.4 ± 1.5 | 13.6 ± 1.2 |
|
| Nasal inner volume (mm3) | 0.0231 ± 0.0047 | 0.0233 ± 0.0048 | 0.0210 ± 0.0032 | 0.890 |
| Superior inner quadrant ( | 15.1 ± 1.6 | 14.5 ± 2 | 13.2 ± 1.2 |
|
| Superior inner volume (mm3) | 0.0222 ± 0.0042 | 0.0222 ± 0.0043 | 0.0205 ± 0.0023 | 0.928 |
| Inferior inner quadrant ( | 14.2 ± 1.4 | 14.8 ± 3.8 | 12.9 ± 1 |
|
| Inferior inner volume (mm3) | 0.0214 ± 0.0035 | 0.0217 ± 0.0051 | 0.02 | 0.956 |
| Temporal outer quadrant ( | 12.7 ± 0.9 | 12.9 ± 0.8 | 12.7 ± 2.2 | 0.277 |
| Temporal outer volume (mm3) | 0.0669 ± 0.0052 | 0.0683 ± 0.0062 | 0.0658 ± 0.0126 | 0.798 |
| Nasal outer quadrant ( | 13.3 ± 1.2 | 14 ± 4.1 | 12.4 ± 1.1 |
|
| Nasal outer volume (mm3) | 0.0075 ± 0.0711 | 0.075 ± 0.0218 | 0.0642 ± 0.0067 | 0.504 |
| Superior outer quadrant ( | 13.8 ± 1.4 | 13.3 ± 1.2 | 12.6 ± 1.1 |
|
| Superior outer volume (mm3) | 0.0728 ± 0.0085 | 0.0706 ± 0.0072 | 0.0668 ± 0.0075 | 0.708 |
| Inferior outer quadrant ( | 12.9 ± 1.1 | 13 ± 1.6 | 12.5 ± 1.1 | 0.120 |
| Inferior outer volume (mm3) | 0.0686 ± 0.006 | 0.0689 ± 0.0096 | 0.0674 ± 0.0148 | 0.832 |
| Average thickness ( | 14.2 ± 1.1 | 14.6 ± 1.4 | 13.3 ± 0.9 | 0.316 |
| Total volume (mm3) | 0.3845 ± 0.0296 | 0.3917 ± 0.0371 | 0.3637 ± 0.0295 | 0.758 |
| Internal quadrant ( | 14.4 ± 1.3 | 14.8 ± 1.4 | 13.4 ± 1.1 |
|
| External quadrant ( | 13.1 ± 0.9 | 13.3 ± 1.4 | 12.5 ± 1.2 | 0.165 |
The results are expressed as mean ± SD. The italicized values indicate a statistically significant difference between the groups: p < 0.05. RPE: retinal pigment epithelium; NPDR-DMO: nonproliferative diabetic retinopathy-diabetic macular oedema; PDR-DMO: proliferative diabetic retinopathy-diabetic macular oedema.
Figure 3Mean RPE layer thickness difference (%) between the eyes from the control group and NPDR-DMO or PDR-DMO.
Post hoc analysis for ETDRS quadrants with a statistically significant difference after the Kruskal-Wallis test.
| RPE thickness | Control vs. NPDR-DMO | Control vs. PDR-DMO | NPDR-DMO vs. PDR-DMO |
|---|---|---|---|
| Central subfield | 0.039 |
| 0.017 |
| Central minimum |
|
| 0.447 |
| Central maximum |
|
| 0.741 |
| Nasal inner quadrant | 0.936 |
|
|
| Superior inner quadrant | 0.322 |
| 0.022 |
| Inferior inner quadrant | 0.660 |
| 0.009 |
| Nasal outer quadrant | 0.841 | 0.0110 | 0.019 |
| Superior outer quadrant | 0.208 | 0.0028 | 0.101 |
| Internal quadrant | 0.976 |
| 0.003 |
The italicized values indicate a statistically significant difference between groups. p < 0.001 adjusted Bonferroni. RPE: retinal pigment epithelium; NPDR-DMO: nonproliferative diabetic retinopathy-diabetic macular oedema; PDR-DMO: proliferative diabetic retinopathy-diabetic macular oedema.
Figure 4Scatterplots between different variables: (a) CMT and central RPE in NPDR-DMO; (b) CMT and central RPE in PDR-DMO; (c) central RPE and BCVA in NPDR-DMO; (d) central RPE and BCVA in PDR-DMO; (e) inner retina and central RPE in NPDR-DMO; (f) inner retina and central RPE in PDR-DMO; (g) central RPE and photoreceptors' thickness in NPDR-DMO; (h) central RPE and photoreceptors' thickness in PDR-DMO.
Correlations between BCVA and retinal layers thickness.
| Correlation | NPDR-DMO |
|
| PDR-DMO |
|
|
|---|---|---|---|---|---|---|
| Central RPE and BCVA | -0.362 | 0.131 | 0.153 | 0.220 | 0.048 | 0.845 |
| Outer retina and BCVA | 0.086 | 0.007 | 0.743 |
| 0.203 | 0.053 |
| CMT and BCVA | -0.368 | 0.136 | 0.146 | -0.119 | 0.014 | 0.654 |
| Photoreceptors and BCVA | -0.0066 | 0 | 0.981 | -0.102 | 0.010 | 0.687 |
| Inner retina and BCVA |
| 0.149 | 0.127 | -0.069 | 0.047 | 0.782 |
| CMT and central RPE |
| 0.517 | 0.0007 | -0.054 | 0.003 | 0.839 |
| Inner retina and central RPE |
| 0.541 | 0.0002 | -0.039 | 0.001 | 0.874 |
| Photoreceptors and RPE | 0.383 | 0.146 | 0.117 | 0.061 | 0.005 | 0.785 |
RPE: retinal pigment epithelium; NPDR-DMO: nonproliferative diabetic retinopathy-diabetic macular oedema; PDR-DMO: proliferative diabetic retinopathy-diabetic macular oedema; CMT: central macular thickness; BCVA: best-corrected visual acuity.